Role of movement in long-term basal ganglia changes: implications for abnormal motor responses

Abnormal involuntary movements (AIMs) and dyskinesias elicited by drugs that stimulate dopamine receptors in the basal ganglia are a major issue in the management of Parkinson's disease (PD). Preclinical studies in dopamine-denervated animals have contributed to the modeling of these abnormal m...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in computational neuroscience 2013-10, Vol.7, p.142-142
Main Authors: Simola, Nicola, Morelli, Micaela, Frazzitta, Giuseppe, Frau, Lucia
Format: Article
Language:English
Subjects:
6-OHDA
Basal ganglia
Behavior
Dopamine
Dopamine receptors
Drug dosages
dynorphin
Dyskinesia
Immobilization
Kinases
Motor task performance
Movement
Movement disorders
Neostriatum
Neurodegenerative diseases
Neuroscience
Neurosciences
Parkinson's disease
priming
Rotational behavior
Signal transduction
striatonigral
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abnormal involuntary movements (AIMs) and dyskinesias elicited by drugs that stimulate dopamine receptors in the basal ganglia are a major issue in the management of Parkinson's disease (PD). Preclinical studies in dopamine-denervated animals have contributed to the modeling of these abnormal movements, but the precise neurochemical and functional mechanisms underlying these untoward effects are still elusive. It has recently been suggested that the performance of movement may itself promote the later emergence of drug-induced motor complications, by favoring the generation of aberrant motor memories in the dopamine-denervated basal ganglia. Our recent results from hemiparkinsonian rats subjected to the priming model of dopaminergic stimulation are in agreement with this. These results demonstrate that early performance of movement is crucial for the manifestation of sensitized rotational behavior, indicative of an abnormal motor response, and neurochemical modifications in selected striatal neurons following a dopaminergic challenge. Building on this evidence, this paper discusses the possible role of movement performance in drug-induced motor complications, with a look at the implications for PD management.
ISSN:1662-5188
1662-5188
DOI:10.3389/fncom.2013.00142